Document Detail


High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer.
MedLine Citation:
PMID:  20798386     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The profound hypogonadism that occurs with androgen deprivation therapy (ADT) for prostate cancer (PCa) results in complications such as diabetes and metabolic syndrome that predispose to cardiovascular disease. Because phytoestrogens have been associated with an improvement in metabolic parameters, we evaluated their role in men undergoing ADT. Our objective was to evaluate the effects of high-dose isoflavones on metabolic and inflammatory parameters in men undergoing ADT. This was a randomized, double-blind, placebo-controlled, 12-week pilot study. Participants were randomly assigned to receive 20 g of soy protein containing 160 mg of total isoflavones vs taste-matched placebo (20 g whole milk protein). The study was conducted at a tertiary care center in the United States. Thirty-three men (isoflavones = 17, placebo = 16) undergoing ADT for PCa completed this pilot study. Mean age in the 2 groups was 69 years and the majority of men were Caucasians. Mean duration of ADT in both groups was approximately 2 years (P = .70). The 2 groups were well matched at baseline. After 12 weeks of intervention, there was no significant difference in either metabolic or inflammatory parameters between the 2 groups. We found that high-dose isoflavones over a course of 12 weeks do not improve metabolic or inflammatory parameters in androgen-deprived men.
Authors:
Joshua K Napora; Ryan G Short; Denis C Muller; Olga D Carlson; Juliana O Odetunde; Xiaoqiang Xu; Michael Carducci; Thomas G Travison; Marcello Maggio; Josephine M Egan; Shehzad Basaria
Related Documents :
18413966 - Effect of manual feeding on the level of farmer's exposure to airborne contaminants in ...
11937236 - Risk factors for gastric ulcers in australian pigs at slaughter.
6726456 - Effect of plane of nutrition on adipose tissue lipid metabolism in genetically obese an...
11533186 - Comparative pathogenesis of tissue culture-adapted and wild-type cowden porcine enteric...
20468656 - Neonatal jaundice.
7276756 - The effect of decreased plasma cholesterol concentration on circulatinga mevalonate met...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-08-26
Journal Detail:
Title:  Journal of andrology     Volume:  32     ISSN:  1939-4640     ISO Abbreviation:  J. Androl.     Publication Date:    2011 Jan-Feb
Date Detail:
Created Date:  2010-12-20     Completed Date:  2011-03-28     Revised Date:  2013-04-12    
Medline Journal Info:
Nlm Unique ID:  8106453     Medline TA:  J Androl     Country:  United States    
Other Details:
Languages:  eng     Pagination:  40-8     Citation Subset:  IM    
Affiliation:
National Institute of Health, National Institute on Aging, Laboratory of Clinical Investigation, Diabetes Section, Baltimore, Maryland, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Androgen Antagonists / therapeutic use*
Androgens / deficiency*
Glucose / metabolism
Humans
Inflammation / metabolism*
Insulin Resistance
Isoflavones / administration & dosage*
Male
Metabolism / drug effects
Pilot Projects
Prostatic Neoplasms / drug therapy*
Soybean Proteins / therapeutic use
Grant Support
ID/Acronym/Agency:
Z01 AG000906-12/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Androgens; 0/Isoflavones; 0/Soybean Proteins; 50-99-7/Glucose
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased risk of benign prostatic enlargement among patients with liver cirrhosis: a nationwide pop...
Next Document:  Pregnancy rate after varicocele repair: how many miscarriages?